Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S027 - Managing Patients with Melanoma or Other Melanocytic Neoplasms

Saturday, February 17; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize how dermoscopy can help when assessing pigmented lesions on the face
  • Identify which patients would benefit from full-body skin screening, genetic testing and sentinel lymph node mapping, as well as which patients would benefit from using imiquimod for treatment
  • Describe the AJCC Staging System changes as they relate to dermatologists

Description

This session will aid dermatologists in creating appropriate management plans for patients with melanoma or at risk for the disease. Topics covered are ones encountered in daily practice, including issues regarding how to approach pigmented lesions on the face, determining which patients would benefit from genetic testing and full-body skin screening, and identifying which melanoma patients would benefit from imiquimod for treatment or sentinel lymph node mapping. This session is geared towards giving the working clinician practical information to assist in formulating management plans. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.

Disclosures

  • Chapman, M. Shane, MD: Celgene Corporation – I(Grants/Research Funding); Genentech, Inc. – A(H); Pfizer Inc. – I(Grants/Research Funding);
  • Chu, Emily Y., MD, PhD: no financial relationships exist with commercial interests.
  • Kim, Caroline C., MD: Hoffman-La Roche Ltd. – I(NC);
  • Leachman, Sancy A., MD, PhD: Castle Biosciences, Inc – A(H); DermDetect – B(Grants/Research Funding); Myriad Genetics Inc – A(H), C(Fees); Palvella Therapeutics – A(NC);
  • Marchetti, Michael Armando, MD: no financial relationships exist with commercial interests.
  • Ming, Michael E., MD: no financial relationships exist with commercial interests.
  • Stein, Jennifer A., MD, PhD: MoleSafe, Inc. – O(Fees); UpToDate, Inc – O(IP);
  • Swetter, Susan M., MD: no financial relationships exist with commercial interests.
Schedule
Saturday, February 17
1:00 PM
Dr. Stein / How can dermoscopy help me with pigmented lesions on the face?
1:18 PM
Dr. Stein / Q&A
1:20 PM
Dr. Swetter / Will Artificial Intelligence (AI) replace dermatologists?
1:40 PM
Dr. Chapman / What is the role of imiquimod in the treatment of melanoma in situ?
2:00 PM
Dr. Kim / What are some practical tips for clinicians taking care of melanoma patients?
2:20 PM
Dr. Kim, Dr. Chapman, and Dr. Swetter / Q&A
2:30 PM
Dr. Leachman / Which patients would benefit from full-body skin screening?
2:50 PM
Dr. Marchetti / Which patients would benefit from genetic testing?
3:10 PM
Dr. Ming / Which melanoma patients would benefit from a sentinel lymph node procedure?
3:30 PM
Dr. Chu / What are the new AJCC Staging System changes, and how will they affect my patients?
3:50 PM
Dr. Ming, Dr. Chu, Dr. Leachman, and Dr. Marchetti / Q&A
Event Details
  • Date
    Saturday, February 17
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 7B
  • CME Credits
    3.00
  • Type
    MOC
Directors/Co-Directors
Speakers
  • Caroline C. Kim, MD, FAAD - Handout
  • Emily Y. Chu, MD, PhD, FAAD - Handout
  • Jennifer A. Stein, MD, PhD, FAAD - Handout
  • M. Shane Chapman, MD, FAAD
  • Michael Armando Marchetti, MD, FAAD - Handout
  • Sancy A. Leachman, MD, PhD, FAAD
  • Susan M. Swetter, MD, FAAD - Handout